Cargando…
Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation
BACKGROUND: China, which has the largest chronic hepatitis B virus (HBV) burden, may expand antiviral therapy to attain the World Health Organization (WHO)-2030 goal of 65% reduction in mortality. We evaluated health outcomes and cost-effectiveness of chronic HBV infection treatments based on alanin...
Autores principales: | Zhang, Sihui, Wang, Chao, Liu, Bei, Lu, Qing-Bin, Shang, Jia, Zhou, Yihua, Jia, Jidong, Xu, Xiaoyuan, Rao, Huiying, Han, Bingfeng, Zhao, Tianshuo, Chen, Linyi, Xie, Mingzhu, Cui, Jiahao, Du, Juan, zeng, Jing, huang, Ninghua, Liu, Yaqiong, Zhang, Lei, Zhuang, Hui, Cui, Fuqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326688/ https://www.ncbi.nlm.nih.gov/pubmed/37424693 http://dx.doi.org/10.1016/j.lanwpc.2023.100738 |
Ejemplares similares
-
Analysis of deaths following yeast-derived hepatitis B vaccination of infants, China, January 2013 to December 2020
por: Zhang, Sihui, et al.
Publicado: (2023) -
Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis
por: Chen, Linyi, et al.
Publicado: (2022) -
Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study
por: Wang, Chao, et al.
Publicado: (2021) -
What Causes the Discrepancy in SARS-CoV-2 Vaccine Between Parental Hesitancy for Themselves and for Their Children During Lockdown Period?
por: Zhao, Tianshuo, et al.
Publicado: (2023) -
12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial
por: Han, Bingfeng, et al.
Publicado: (2021)